Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same

• US 20080108110A1
• Filed: 10/03/2007
• Published: 05/08/2008
• Est. Priority Date: 04/02/1998
• Status: Abandoned Application

• Current Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Original Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Inventors: Sismey-Ragatz, Alison, DeAngelis, Paul
• Application Number:
  US11/906,676
• Publication Number:
  US 20080108110A1
• Time in Patent Office: Days
• US Class Current: 435/84
• CPC Class Codes: A61K 39/102 Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61L 24/08 Polysaccharides A61L24/043 takes precedence
• CPC Class Codes: A61L 27/20 Polysaccharides
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: C07H 3/06 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: C07H 5/04 to nitrogen
• CPC Class Codes: C07K 14/285 from Pasteurellaceae (F), e.g. Haemophilus influenza
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C08B 37/0063 Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
• CPC Class Codes: C08B 37/0069 Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
• CPC Class Codes: C08B 37/0072 Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
• CPC Class Codes: C08B 37/0075 Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: C12N 9/1048 Glycosyltransferases (2.4)
• CPC Class Codes: C12N 9/1051 Hexosyltransferases (2.4.1)
• CPC Class Codes: C12P 19/04 Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• CPC Class Codes: C12P 19/26 Preparation of nitrogen-containing carbohydrates
• CPC Class Codes: C12P 19/28 : N-glycosides
• CPC Class Codes: C12Q 1/689 : for bacteria

Abstract

The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate or chondroitin or heparin/heparosan synthases from Pasteurella, in order to create a variety of glycosaminoglycan oligosaccharides having a natural or chimeric or hybrid sugar structure with a targeted size that are substantially monodisperse in size. The present invention also relates to methodology for polymer grafting by a polysachharide synthase to form glycosaminoglycan polymers having an unnatural structure.

Claims

1. A method for enzymatically producing glycosaminoglycan polymers having unnatural structures, the method comprising the steps of:

providing at least one functional acceptor, wherein the functional acceptor has at least one sugar unit selected from the group consisting of uronic acid, hexosamine and structural variants or derivatives thereof;

providing at least one recombinant glycosaminoglycan transferase having an empty acceptor site and being capable of elongating the at least one functional acceptor to form extended glycosaminoglycan-like molecules;

providing at least one UDP-sugar analog, wherein the at least one UDP-sugar analog is not found in mammals in a native state; and

wherein the at least one recombinant glycosaminoglycan transferase elongates the at least one functional acceptor to provide glycosaminoglycan polymers wherein the glycosaminoglycan polymers have an unnatural structure.

2. The method of claim 1 wherein, in the step of providing at least one UDP-sugar analog, the at least one UDP-sugar analog is selected from the group consisting of UDP-GlcN, UDP-GlcNAcUA, UDP-GlcNAcNAc, UDP-GlcdiNAcUA, UDP-GlcN[TFA], UDP-GlcNBut, UDP-GlcNPro, UDP-6-F-6-deoxyGlcNAc, UDP-2-F-2-deoxyGlcUA, and combinations thereof.

3. The method of claim 1 wherein, in the step of providing at least one functional acceptor, the functional acceptor is at least one of:

(a) an HA oligosaccharide, polysaccharide or polymer;

(b) a chondroitin oligosaccharide, polysaccharide or polymer;

(c) a chondroitin sulfate oligosaccharide, polysaccharide or polymer;

(d) a heparosan oligosaccharide, polysaccharide or polymer;

(e) a heparin oligosaccharide, polysaccharide or polymer;

(f) a heparan oligosaccharide, polysaccharide or polymer;

(g) an acceptor comprising a glycoside of uronic acid; and

(h) an extended acceptor selected from the group consisting of HA chains, chondroitin chains, heparosan chains, mixed glycosaminoglycan chains, analog containing chains, and combinations thereof.

4. The method of claim 1 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase is selected from the group consisting of a recombinant hyaluronan synthase or active fragment or mutant thereof, a recombinant chondroitin synthase or active fragment or mutant thereof, a recombinant heparosan synthase or active fragment or mutant thereof and combinations thereof.

5. The method of claim 1 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase comprises a recombinant glycosyltransferase capable of adding only one of GlcUA, GlcNAc, Glc, GalNAc, GlcN, GalN or a structural variant or derivative thereof.

6. The method of claim 1 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase comprises a recombinant synthetic chimeric glycosaminoglycan transferase capable of adding two or more of GlcUA, GlcNAc, Glc, GalNAc, GlcN, GalN and a structural variant or derivative thereof.

7. The method of claim 1 wherein, in the step of providing the at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase is selected from the group consisting of:

(a) a recombinant glycosaminoglycan transferase having an amino acid sequence essentially as set forth in SEQ ID NO;

2, 4, 6, 8, 9, 66, 70 or 71;

(b) a recombinant glycosaminoglycan transferase encoded by a nucleotide sequence essentially as set forth in SEQ ID NO;

1, 3, 5, 7, 10-46, 65 or 67;

(c) a recombinant glycosaminoglycan transferase encoded by a nucleotide sequence capable of hybridizing to a complement of a nucleotide sequence selected from the group consisting of SEQ ID NOS;

1, 3, 5, 7, 10-46, 65 or 67 under hybridization conditions comprising hybridization at a temperature of 68°

C. in 5×

SSC/5×

Denhardt'"'"'s solution/1.0% SDS, followed with washing in 3×

SSC at 42°

C.; and

(d) a chimeric recombinant glycosaminoglycan transferase having an amino acid sequence essentially as set forth in SEQ ID NO;

47 or 48.

8. The method of claim 1 wherein, in the step of providing at least one functional acceptor, the at least one functional acceptor further comprises a moiety selected from the group consisting of a fluorescent tag, a radioactive tag or therapeutic, an affinity tag, a detection probe, a medicant, a biologically active agent, a therapeutic agent, and combinations thereof.

9. The method of claim 1 wherein, in the step of providing at least one UDP-sugar analog, the at least one UDP-sugar analog further comprises a moiety selected from the group consisting of a fluorescent tag, a radioactive tag or therapeutic, an affinity tag, a detection probe, a medicant, a biologically active agent, a therapeutic agent, and combinations thereof.

10. A method for enzymatically producing glycosaminoglycan polymers having unnatural structures, the method comprising the steps of:

providing at least one functional acceptor, wherein the functional acceptor has at least one sugar unit selected from the group consisting of uronic acid, hexosamine and structural variants or derivatives thereof;

providing at least one recombinant glycosaminoglycan transferase having an empty acceptor site and being capable of elongating the at least one functional acceptor to form extended glycosaminoglycan-like molecules; and

providing at least one UDP-sugar selected from the group consisting of UDP-GlcUA, UDP-GlcNAc, UDP-Glc, UDP-GalNAc, UDP-GlcN, UDP-GalN and structural variants or derivatives thereof; and

providing at least one UDP-sugar analog, wherein the at least one UDP-sugar analog that is not found in mammals in a native state; and

wherein the at least one recombinant glycosaminoglycan transferase elongates the at least one functional acceptor to provide glycosaminoglycan polymers wherein the glycosaminoglycan polymers have an unnatural structure.

11. The method of claim 10 wherein, in the step of providing at least one UDP-sugar analog, the at least one UDP-sugar analog is selected from the group consisting of UDP-GlcN, UDP-GlcNAcUA, UDP-GlcNAcNAc, UDP-GlcdiNAcUA, UDP-GlcN[TFA], UDP-GlcNBut, UDP-GlcNPro, UDP-6-F-6-deoxyGlcNAc, UDP-2-F-2-deoxyGlcUA, and combinations thereof.

12. The method of claim 10 wherein, in the step of providing at least one functional acceptor, the functional acceptor is at least one of:

(a) an HA oligosaccharide, polysaccharide or polymer;

(b) a chondroitin oligosaccharide, polysaccharide or polymer;

(c) a chondroitin sulfate oligosaccharide, polysaccharide or polymer;

(d) a heparosan oligosaccharide, polysaccharide or polymer;

(e) a heparin oligosaccharide, polysaccharide or polymer;

(f) a heparan oligosaccharide, polysaccharide or polymer;

(g) an acceptor comprising a glycoside of uronic acid; and

(h) an extended acceptor selected from the group consisting of HA chains, chondroitin chains, heparosan chains, mixed glycosaminoglycan chains, analog containing chains, and combinations thereof.

13. The method of claim 10 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase is selected from the group consisting of a recombinant hyaluronan synthase or active fragment or mutant thereof, a recombinant chondroitin synthase or active fragment or mutant thereof, a recombinant heparosan synthase or active fragment or mutant thereof and combinations thereof.

14. The method of claim 10 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase comprises a recombinant glycosyltransferase capable of adding only one of GlcUA, GlcNAc, Glc, GalNAc, GlcN, GalN or a structural variant or derivative thereof.

15. The method of claim 10 wherein, in the step of providing at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase comprises a recombinant synthetic chimeric glycosaminoglycan transferase capable of adding two or more of GlcUA, GlcNAc, Glc, GalNAc, GlcN, GalN and a structural variant or derivative thereof.

16. The method of claim 10 wherein, in the step of providing the at least one recombinant glycosaminoglycan transferase, the at least one recombinant glycosaminoglycan transferase is selected from the group consisting of:

(a) a recombinant glycosaminoglycan transferase having an amino acid sequence essentially as set forth in SEQ ID NO;

2, 4, 6, 8, 9, 66, 70 or 71;

(b) a recombinant glycosaminoglycan transferase encoded by a nucleotide sequence essentially as set forth in SEQ ID NO;

1, 3, 5, 7, 10-46, 65 or 67;

(c) a recombinant glycosaminoglycan transferase encoded by a nucleotide sequence capable of hybridizing to a complement of a nucleotide sequence selected from the group consisting of SEQ ID NOS;

1, 3, 5, 7, 10-46, 65 or 67 under hybridization conditions comprising hybridization at a temperature of 68°

C. in 5×

SSC/5×

Denhardt'"'"'s solution/1.0% SDS, followed with washing in 3×

SSC at 42°

C.; and

(d) a chimeric recombinant glycosaminoglycan transferase having an amino acid sequence essentially as set forth in SEQ ID NO;

47 or 48.

17. The method of claim 10 wherein, in the step of providing at least one functional acceptor, the at least one functional acceptor further comprises a moiety selected from the group consisting of a fluorescent tag, a radioactive tag or therapeutic, an affinity tag, a detection probe, a medicant, a biologically active agent, a therapeutic agent, and combinations thereof.

18. The method of claim 10 wherein, in the step of providing at least one UDP-sugar analog, the at least one UDP-sugar analog further comprises a moiety selected from the group consisting of a fluorescent tag, a radioactive tag or therapeutic, an affinity tag, a detection probe, a medicant, a biologically active agent, a therapeutic agent, and combinations thereof.

19. A recombinantly produced, isolated glycosaminoglycan polymer having an unnatural structure, wherein the glycosaminoglycan polymer comprises at least one sugar analog that is not found in mammals in a native state.

20. The recombinantly produced, isolated glycosaminoglycan polymer of claim 19, wherein the at least one sugar analog is selected from the group consisting of UDP-GlcN, UDP-GlcNAcUA, UDP-GlcNAcNAc, UDP-GlcdiNAcUA, UDP-GlcN[TFA], UDP-GlcNBut, UDP-GlcNPro, UDP-6-F-6-deoxyGlcNAc, UDP-2-F-2-deoxyGlcUA, and combinations thereof.

21. The recombinantly produced, isolated glycosaminoglycan polymer of claim 19, wherein the polymer further comprises at least one of:

(a) an HA oligosaccharide, polysaccharide or polymer;

(b) a chondroitin oligosaccharide, polysaccharide or polymer;

(c) a chondroitin sulfate oligosaccharide, polysaccharide or polymer;

(d) a heparosan oligosaccharide, polysaccharide or polymer;

(e) a heparin oligosaccharide, polysaccharide or polymer;

(f) a heparan oligosaccharide, polysaccharide or polymer;

(g) an acceptor comprising a glycoside of uronic acid; and

(h) an extended acceptor selected from the group consisting of HA chains, chondroitin chains, heparosan chains, mixed glycosaminoglycan chains, analog containing chains, and combinations thereof.

22. The recombinantly produced, isolated glycosaminoglycan polymer of claim 19, wherein the polymer further comprises a moiety selected from the group consisting of a fluorescent tag, a radioactive tag or therapeutic, an affinity tag, a detection probe, a medicant, a biologically active agent, a therapeutic agent, and combinations thereof.

23. A recombinantly produced, isolated glycosaminoglycan polymer having an unnatural structure, comprising:

a glycosaminoglycan selected from the group consisting of an HA oligosaccharide, an HA polymer, a chondroitin oligosaccharide, a chondroitin polymer, a chondroitin sulfate polymer, a heparosan oligosaccharide, a heparin polymer, a heparin polymer, a heparosan polymer, and combinations thereof; and

at least one sugar analog that is not found in mammals in a native state, wherein the at least one sugar analog is selected from the group consisting of UDP-GlcN, UDP-GlcNAcUA, UDP-GlcNAcNAc, UDP-GlcdiNAcUA, UDP-GlcN[TFA], UDP-GlcNBut, U DP-GlcNPro, UDP-6-F-6-deoxyGlcNAc, UDP-2-F-2-deoxyGlcUA, and combinations thereof.

24. The recombinantly produced, isolated glycosaminoglycan polymer of claim 23, wherein the polymer further comprises a moiety selected from the group consisting of a fluorescent tag, a radioactive tag or therapeutic, an affinity tag, a detection probe, a medicant, a biologically active agent, a therapeutic agent, and combinations thereof.

25. A method for doing business, comprising the steps of:

providing at least one functional acceptor, wherein the functional acceptor has at least one sugar unit selected from the group consisting of uronic acid, hexosamine and structural variants or derivatives thereof;

providing at least one recombinant glycosaminoglycan transferase having an empty acceptor site and being capable of elongating the at least one functional acceptor to form extended glycosaminoglycan-like molecules;

providing at least one UDP-sugar analog, wherein the at least one UDP-sugar analog is not found in mammals in a native state;

wherein the at least one recombinant glycosaminoglycan transferase elongates the at least one functional acceptor to provide glycosaminoglycan polymers wherein the glycosaminoglycan polymers have an unnatural structure; and

selling and delivering the glycosaminoglycan polymers having an unnatural structure to a customer.